SiBone (SIBN) Expected to Post Earnings on Monday

SiBone (NASDAQ:SIBN) is projected to post its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect SiBone to post earnings of ($0.13) per share and revenue of $55.31 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 2, 2026 at 4:30 PM ET.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.06. SiBone had a negative net margin of 6.85% and a negative return on equity of 8.23%. The company had revenue of $56.01 million for the quarter, compared to analysts’ expectations of $55.34 million. On average, analysts expect SiBone to post ($0.40) EPS for the current fiscal year and ($0.33) EPS for the next fiscal year.

SiBone Price Performance

NASDAQ SIBN opened at $21.48 on Monday. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.15 and a quick ratio of 7.55. The company’s 50 day simple moving average is $19.16 and its 200 day simple moving average is $16.85. SiBone has a 12 month low of $11.48 and a 12 month high of $21.89. The company has a market capitalization of $952.64 million, a P/E ratio of -63.18 and a beta of 0.66.

Insider Buying and Selling

In other SiBone news, SVP Michael A. Pisetsky sold 3,133 shares of the firm’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $18.17, for a total value of $56,926.61. Following the completion of the transaction, the senior vice president directly owned 270,517 shares in the company, valued at $4,915,293.89. This trade represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey Dunn sold 20,000 shares of the firm’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $18.47, for a total transaction of $369,400.00. Following the completion of the transaction, the director owned 16,057 shares of the company’s stock, valued at approximately $296,572.79. The trade was a 55.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 224,968 shares of company stock worth $4,368,118 in the last quarter. 4.00% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts recently weighed in on SIBN shares. UBS Group raised their target price on shares of SiBone from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Weiss Ratings raised SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. Truist Financial upped their price target on SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. Finally, TD Cowen increased their price objective on SiBone from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $24.50.

SiBone Company Profile

SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.